Wall Street analysts expect Aileron Therapeutics (NASDAQ:ALRN) to announce earnings per share (EPS) of ($0.49) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Aileron Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.48). The business is expected to issue its next quarterly earnings results on Monday, July 2nd.
According to Zacks, analysts expect that Aileron Therapeutics will report full-year earnings of ($2.06) per share for the current fiscal year, with EPS estimates ranging from ($2.24) to ($1.95). For the next fiscal year, analysts forecast that the firm will report earnings of ($2.24) per share, with EPS estimates ranging from ($2.26) to ($2.22). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that follow Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings results on Monday, April 2nd. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.03).
Separately, Zacks Investment Research raised shares of Aileron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $19.33.
Shares of ALRN stock traded down $0.36 on Friday, hitting $6.37. The stock had a trading volume of 33,640 shares, compared to its average volume of 30,459. Aileron Therapeutics has a twelve month low of $6.22 and a twelve month high of $15.48. The firm has a market capitalization of $99.16 and a price-to-earnings ratio of -3.60.
In related news, major shareholder Apple Tree Partners Ii Lp sold 150,000 shares of the company’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $9.80, for a total value of $1,470,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 68.10% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALRN. California State Teachers Retirement System acquired a new position in Aileron Therapeutics in the 3rd quarter worth $110,000. Vanguard Group Inc. acquired a new position in Aileron Therapeutics in the 2nd quarter worth $111,000. Bank of New York Mellon Corp acquired a new position in Aileron Therapeutics in the 3rd quarter worth $135,000. Schwab Charles Investment Management Inc. acquired a new position in Aileron Therapeutics in the 3rd quarter worth $165,000. Finally, Endurant Capital Management LP boosted its stake in Aileron Therapeutics by 24.0% in the 4th quarter. Endurant Capital Management LP now owns 85,997 shares of the company’s stock worth $906,000 after purchasing an additional 16,647 shares during the period. 7.63% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/aileron-therapeutics-alrn-expected-to-announce-earnings-of-0-49-per-share.html.
About Aileron Therapeutics
Aileron Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation.
Get a free copy of the Zacks research report on Aileron Therapeutics (ALRN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.